|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Noncash impairment | |||||
| Cost of goods sold | |||||
| Gross profit | |||||
| Operating expenses | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Research and development | |||||
| Total operating expenses | |||||
| Gain on sale of assets | |||||
| Operating income | |||||
| Interest expense | |||||
| Investment in equity securities - unrealized loss | |||||
| Loss on extinguishment of debt | |||||
| Other income, net | |||||
| Income before income taxes | |||||
| Income tax expense | |||||
| Net income | |||||
| Net income per common share: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average common shares outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...